Literature DB >> 20174762

Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin.

Fiona Newall1, Vera Ignjatovic, Linda Johnston, Robyn Summerhayes, Geoff Lane, Noel Cranswick, Paul Monagle.   

Abstract

Previous studies investigating continuous unfractionated heparin (UFH) therapy report age-related differences in UFH response in children, as measured by APTT and anti-Xa assay. This study determined the age-related response following administration of a single UFH bolus of 75-100 IU/kg in children. Venous blood samples were collected from children (n=56) at 15, 30, 45 and 120 minutes post-UFH. Anti-Xa, anti-IIa, APTT, TCT and protamine titration were performed on all samples. Age-dependent differences in the effect and concentration of UFH were identified for the anti-Xa, anti-IIa and protamine titration assays, respectively. In addition, a trend suggesting a proportional increase in anti-Xa and anti-IIa-mediated UFH effect with age was evident. Logistic regression demonstrated an increase in protamine titration of 0.6 IU/ml for every year of age in samples collected 15 minutes post-UFH. UFH-mediated anti-IIa activity was reduced compared to anti-Xa activity across childhood, with a two-fold increase in anti-Xa to anti-IIa ratio in infants less than one year of age compared to teenagers in the setting of high UFH concentrations. This study demonstrates that the previously reported age-dependent response to UFH occurs in the context of an age-dependent serum concentration of UFH. The trend toward increased UFH serum concentration and anticoagulant activity with age may be related to short-term differences in UFH binding to coagulant and competitive plasma proteins in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20174762     DOI: 10.1160/TH09-09-0624

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.

Authors:  Donald L Yee; Sarah H O'Brien; Guy Young
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

3.  Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.

Authors:  Hesham Al-Sallami; Fiona Newall; Paul Monagle; Vera Ignjatovic; Noel Cranswick; Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

4.  Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials.

Authors:  Hugo Maas; Savion Gropper; Fenglei Huang; Joachim Stangier; Igor Tartakovsky; Martina Brueckmann; Jacqueline M L Halton; Lesley G Mitchell
Journal:  Thromb Haemost       Date:  2018-08-15       Impact factor: 5.249

5.  Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization.

Authors:  Maria L Avila; Prakeshkumar S Shah; Leonardo R Brandão
Journal:  Cochrane Database Syst Rev       Date:  2020-02-17

Review 6.  Hematologic concerns in extracorporeal membrane oxygenation.

Authors:  Jonathan Sniderman; Paul Monagle; Gail M Annich; Graeme MacLaren
Journal:  Res Pract Thromb Haemost       Date:  2020-05-15

7.  Gene-based anticoagulation regimens for an infant after mitral-valve replacement: A case report.

Authors:  Hua Cao; Xiaotong Xia; Jinglan Fu; Tingting Wu; Wenjun Chen; Ying Dai; Xuan Xia; Jinhua Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.